View Post

ASCO’s Selection of the Most Important Recent Clinical Advances in Breast Cancer

In In The News by Barbara Jacoby

By: Rosana Gnanajothy, MD From: ASCO’s Clinical Cancer Advances 2020 report highlights some of the important advances made in the treatment of breast cancer within the past year. In 2019, ado-trastuzumab emtansine (T-DM1) was approved in the adjuvant setting for HER2-positive patients with residual disease following neoadjuvant therapy. This was an important development following the findings of the KATHERINE …